2,963
Views
41
CrossRef citations to date
0
Altmetric
Research Article

Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect

, , , , , , & show all
Pages 538-545 | Received 13 Mar 2015, Accepted 24 Apr 2015, Published online: 28 May 2015

Figures & data

Figure 1. (A) Cytotoxic effect of rabeprazole (RABE), pantoprazole (PANTO), omeprazole (OME), esomeprazole (ESO) and lansoprazole (LANSO) against Me30966 human melanoma metastatic cells in unbuffered conditions, at different drug dosages and after 48 h of treatment. (B) Apoptosis evaluation of Me30966 human melanoma metastatic cells in unbuffered conditions treated with rabeprazole, pantoprazole, omeprazole, esomeprazole and lansoprazole at different drug dosages and after 48 h of treatment. Columns, mean percentages of cell death of three independent experiments run in triplicate; bars indicate SD. *Indicates p < 0.001.

Figure 1. (A) Cytotoxic effect of rabeprazole (RABE), pantoprazole (PANTO), omeprazole (OME), esomeprazole (ESO) and lansoprazole (LANSO) against Me30966 human melanoma metastatic cells in unbuffered conditions, at different drug dosages and after 48 h of treatment. (B) Apoptosis evaluation of Me30966 human melanoma metastatic cells in unbuffered conditions treated with rabeprazole, pantoprazole, omeprazole, esomeprazole and lansoprazole at different drug dosages and after 48 h of treatment. Columns, mean percentages of cell death of three independent experiments run in triplicate; bars indicate SD. *Indicates p < 0.001.

Figure 2. (A) Cytotoxic effect of omeprazole, esomeprazole and lansoprazole against SaOS2 osteosarcoma, (B) U87 glioblastoma in unbuffered conditions, at different drug dosages and after 48 h of treatment. Columns, mean percentages of cell death of three independent experiments run in triplicate; bars indicate SD. *Indicates p < 0.05.

Figure 2. (A) Cytotoxic effect of omeprazole, esomeprazole and lansoprazole against SaOS2 osteosarcoma, (B) U87 glioblastoma in unbuffered conditions, at different drug dosages and after 48 h of treatment. Columns, mean percentages of cell death of three independent experiments run in triplicate; bars indicate SD. *Indicates p < 0.05.

Figure 3. Cytotoxic (A) and proliferative (B) effects of omeprazole, esomeprazole and lansoprazole against human Me30966 melanoma metastatic cells treated in unbuffered conditions for 48 h and at different drug dosages. Columns, mean percentages of cell death of three independent experiments run in triplicate; bars indicate SD. *Indicates p < 0.05.

Figure 3. Cytotoxic (A) and proliferative (B) effects of omeprazole, esomeprazole and lansoprazole against human Me30966 melanoma metastatic cells treated in unbuffered conditions for 48 h and at different drug dosages. Columns, mean percentages of cell death of three independent experiments run in triplicate; bars indicate SD. *Indicates p < 0.05.

Figure 4. Cytotoxic (A) effects of lansoprazole against human Me30966 melanoma metastatic cells treated in unbuffered conditions, at different drug dosages, for 48 h (dark columns) and for 48 h of treatment and 96 h of recovery in absence of drug (gray columns). Columns, mean percentages of cell death of three independent experiments run in triplicate; bars indicate SD and proliferative (B) proliferative effects lansoprazole against human Me30966 melanoma metastatic cells treated in unbuffered conditions, at different drug dosages, for 48 h (diamond line) and for 48 h of treatment and 96 h of recovery in absence of drug (dotted line).

Figure 4. Cytotoxic (A) effects of lansoprazole against human Me30966 melanoma metastatic cells treated in unbuffered conditions, at different drug dosages, for 48 h (dark columns) and for 48 h of treatment and 96 h of recovery in absence of drug (gray columns). Columns, mean percentages of cell death of three independent experiments run in triplicate; bars indicate SD and proliferative (B) proliferative effects lansoprazole against human Me30966 melanoma metastatic cells treated in unbuffered conditions, at different drug dosages, for 48 h (diamond line) and for 48 h of treatment and 96 h of recovery in absence of drug (dotted line).

Figure 5. In vivo effects of omeprazole (OME), esomeprazole (ESO) and lansoprazole (LANSO) in SCID mice xenografted with human Me30966 melanoma cells. Saline corresponds to the group of control mice. Mice were divided into four experimental groups of five mice each. Once tumors became evident, PPIs were administered (12.5 mg/kg), four times per week, by intraperitoneal injection. Bars indicate SD, p < 0.05.

Figure 5. In vivo effects of omeprazole (OME), esomeprazole (ESO) and lansoprazole (LANSO) in SCID mice xenografted with human Me30966 melanoma cells. Saline corresponds to the group of control mice. Mice were divided into four experimental groups of five mice each. Once tumors became evident, PPIs were administered (12.5 mg/kg), four times per week, by intraperitoneal injection. Bars indicate SD, p < 0.05.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.